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646 The Journal of Thoracic and CardioObjectives: Cellular cardiomyoplasty with isolated skeletal myoblasts and bone
marrow mononuclear cells is an encouraging therapeutic strategy for heart failure.
We investigated the achievements accomplished with combined cell therapy of
skeletal myoblast and bone marrow mononuclear cell transplantation to the ischemic
canine myocardium.
Methods: Autologous skeletal myoblasts (1  108) and autologous bone marrow
mononuclear cells (3  106) were injected directly into the damaged myocardium
of canine hearts that had undergone 2 weeks of left anterior descending coronary
artery ligation. Treatment groups were as follows: skeletal myoblasts plus bone
marrow mononuclear cells (combined cell therapy, n  4), myoblasts (n  4), bone
marrow mononuclear cells (n 4), and medium only (n 4). In similarly designed
supporting experiments, angiogenic factor expression was evaluated by enzyme-
linked immunosorbent assay after cell transplantation in rat hearts that had under-
gone left anterior descending coronary artery ligation.
Results: Four weeks after cell implantation, echocardiography demonstrated better
cardiac performance with reduced left ventricular dilation and significantly im-
proved ejection fraction in the combined cell therapy group compared with that seen
in the other groups (pretreatment, 37.7%  1.1%, vs combined cell therapy, 55.4%
 8.6%; myoblasts, 47.4%  7.4%; bone marrow mononuclear cells, 44.4% 
6.7%; medium only [control], 34.4% 5.4%; P .05). A significantly high number
of neovessels were observed in the group receiving combined cell therapy only
(combined cell therapy, 45.5  12  102/mm2; myoblasts, 26.5  8  102/mm2;
bone marrow mononuclear cells, 30.7 15 102/mm2; medium only [control], 7.1
 1  102/mm2; P  .05). Immunostained sections expressed the skeletal specific
marker myosin heavy chain, although they did not express the cardiac specific
marker troponin T. Results of enzyme-linked immunosorbent assay showed the
highest expression of vascular endothelial growth factor (combined cell therapy, 2.9
 0.7 ng/g tissue; myoblasts, 0.24  0.7 ng/g tissue; bone marrow mononuclear
cells, 1.9  0.2 ng/g tissue; medium only [control], 0.19  0.004 ng/g tissue; P 
.05) and hepatocyte growth factor in the combined cell therapy hearts.
Conclusions: Combined autologous cellular therapy induced both myogenesis and
angiogenesis with enhancement of cardiac performance and reduction of cardiac
remodeling, suggesting a capable strategy for treating severe ischemic cardiomy-
opathy clinically.
After myocardial infarction, left ventricular (LV) chamber remodeling, scarformation, scar expansion, and continuous engulfment of the neighboringcardiomyocytes to the scar are ineluctable. LV heart failure and death is the
unfortunate result because the heart lacks enough regenerative capacity. In this
regard cellular cardiomyoplasty has been reported to have the potential of funda-
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Pmental regenerative capability and has already been intro-
duced in clinical trials with skeletal myoblasts (SMs)1 or
bone marrow mononuclear cells (BM-MNCs),2 and results
suggest that it is a relatively feasible and safe therapy.
Autologous availability of these cells leaves all the ethical
and immunologic issues behind.
The SMs are the mononucleated precursors to skeletal
myofibers with graft generation capacity and have been
widely selected for cell transplantation. Several reported
works showed the limitation of scar area and attenuation of
LV chamber with myoblast transplantation, leading to im-
proved cardiac performance.3-5 Myoblast qualities, such as
being myoregenerative and resistant to ischemia,6 with
growth to millions in a short period of time and transfor-
mation to slow twitch manner,7 suits them for the clinical
cellular cardiomyoplasty application.
In the ischemic myocardium myogenesis has been pro-
posed for repairing the impaired heart functions and was
achieved with SM cell transplantation; however, dominated
regional blood flow defect in ischemic hearts, possible in-
creased death of transplanted myoblasts, and restricted
myoblast survival and growth are a few important limita-
tions8 and must be addressed. Supply of angiogenic and
growth factors enhances the efficacy of cellular cardiomy-
oplasty and appears to be beneficial to the transplanted
cells.9 Given this body of evidence, we established the
combined cell therapy (CCT) concept, myoangiogenesis,
for heart regeneration and improvement in cardiac perfor-
mance.10
Bone marrow (BM) is a soft spongy tissue found within
long bones. In addition to the blood cells, BM has multi-
potential mononuclear cells (MNCs) that contain various
kinds of cell lineages, such as hematopoietic cells, fibro-
blasts, osteoblasts, and myogenic cells, as well as endothe-
lial lineage. A subset of BM-MNCs demonstrates the dif-
ferentiation to endothelial cells,11,12 whereas recent findings
have confirmed the nontransdifferentiation of bone marrow
cells (BMCs) into cardiomyocytes.13 Revascularization by
BM-MNCs has the potential to improve ischemic area per-
fusion and cardiac function.14,15 BM-MNCs cause angio-
genesis by releasing angiogenic factors, such as vascular
endothelial growth factor (VEGF) and basic fibroblast
growth factor (bFGF),11,15,16 and appeals as a suitable can-
didate for CCT.
In the present study we hypothesized that the myoblast
transplantation might reremodel the heart, and the addition
of BM-MNCs for angiogenesis and growth factor supply
might enhance the effect of myoblast transplantation, lead-
ing to further improvement in cardiac performance as the
autologous CCT.
Methods
Sixteen female canines (beagles, 7-8 months old; Oriental Yeast,
Co Ltd, Osaka, Japan) weighing 8 to 10 kg were used in these
The Journal of Thoraciexperiments. Beagles were anesthetized with intravenous admin-
istration of sodium pentobarbital (10 mg/kg). Anesthesia was
maintained with 1% sevoflurane inhalation after mechanical ven-
tilation endotracheal intubation was performed. Left thoracotomy
was performed through the fourth intercostal space, and a pericar-
diotomy was made. The left anterior descending coronary artery
(LAD) was carefully dissected and ligated just distal of the first
diagonal branch arising. Experimentally, myocardial infarction
resulted in a less than 5% acute mortality rate within 24 hours of
the operation, whereas the cell implantation procedure caused no
additional animal deaths. The cultured autologous myoblasts and
freshly isolated autologous BM-MNCs were transplanted. The
pericardium and chest were closed in layers. In supporting exper-
iments rat LADs (Wistar Lewis; 180-220 g; Seas Yoshitomi Ltd)
were similarly ligated, and cells from syngeneic rats were trans-
planted. Rat model animals were merely used to evaluate the
expression of growth factors. All animals received human care in
compliance with the “Principles of laboratory Animal Care” for-
mulated by the National Society for Medical Research and the
“Guide for the Care and Use of Laboratory Animals” prepared by
the institute of laboratory Animal Resource and published by the
National institutes of Health (National Institutes of Health publi-
cation no. 86-23, revised 1985).
Myoblast Isolation Procedure
In canine experiments the autologous tibialis anterior muscle was
removed (weight, 4-6 g) and placed in ice-cold normal saline
solution. Connective tissues and tendons were carefully removed
to minimize the presence of fibroblasts. The isolated muscle was
minced and then treated with 1% collagenase in Dulbecco’s mod-
ified Eagle’s medium (DMEM; Gibco BRL). Percoll (Percoll
Amersham Biosciences) density centrifugation was carried out to
obtain high-purity myoblast cultures. The cells were cultured in
DMEM containing 20% fetal bovine serum and 1% antibiotics.
First-week cultures contained 70% to 80% myoblasts, and at the
time of cell transplantation, the cultures contained more than 60%
myoblasts, as checked by means of desmin staining. Cultured
myoblasts (1  108) were transplanted to canine hearts after 14
days of LAD ligation.
In rat experiments the myoblasts were isolated from the tibialis
anterior muscle of syngeneic rats by using a similar protocol.
Cultured myoblasts (1  107) were transplanted after 14 days of
LAD ligation in rat hearts.
Extraction of BM-MNCs
The canines were anesthetized, and the BM (20 mL) was aspi-
rated from the ileum with a BM harvest needle. About 20 mL of
collected heparinized BM is mixed with saline solution suspended
over the Percoll gradient (Lymphoprep Tube, Nycomed) in a
sterile 50-mL plastic tube and centrifuged at 800g for 20 minutes.
The cells were collected from the interface, washed several times,
and then suspended at a concentration of 3  106 in 1 mL of
DMEM for transplantation. The cells were stored in the ice box for
transplantation.
Rat BM was aspirated by isolating the femur and humerus
bones, dissecting them, and flushing the BM with 5 mL of medium
with a 21-gauge needle. BM-MNCs were collected by the protocol
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single animal heart.
BM-MNC/SM Transplantation Target Region
Cultured autologous myoblasts and freshly extracted autologous
BM-MNCs were separately suspended in 1 to 2 mL of DMEM
solution and injected into the intramyocardium with a 26-gauge
needle. For rat hearts, SMs and BM-MNCs were also separately
suspended in 0.1 to 0.2 mL of DMEM and injected into the
intramyocardium with a 30-gauge needle. Eight to 10 sites for each
cell type, in close proximity to each other, were chosen for cell
injection within and around the scarred area. The injection points
were sutured to mark the locations. Maximum technical care was
taken to avoid loss of cells. In CCT group hearts the ratio of
transplanted myoblasts to BM-MNCs was around 33:1.
Assessment of Cardiac Performance
Dogs were anesthetized, and heart function was monitored at
baseline (2 weeks after LAD ligation) and at 4 weeks after cell
transplantation. Echocardiography was performed with an ultra-
sound machine (SONOS 5500, Agilent Technologies) equipped
with an annular-array transducer operating at 12 MHz. Parasternal
short-axis and long-axis views in B and M imaging modes were
performed. The heart was imaged in the 2-dimensional mode in the
short-axis views at the level of largest ventricular diameter, and
then the systolic and diastolic diameter was determined. The LV
end-systolic dimension was measured at the time of the most
anterior systolic motion of the LV posterior wall, whereas diastolic
measurements were made at the time of apparent maximal LV
diastolic dimension. Global parameters, such as the LV end-
diastolic diameters, end-systolic diameters, and ejection fraction
(EF), were determined. End-diastolic area (EDA) and end-systolic
area (ESA) were also determined to evaluate the percentage of
fractional area shortening (FAS) by using the following formula:
FAS %  EDA  ESA  100 %.
Histopathology
After 4 weeks of treatment, the canine hearts were removed and
cryoprotected in liquid nitrogen and paraffin. Thin sections (5 m
in thickness) of each 5-mm short-axis slice were stained with
hematoxylin and eosin for visualization of muscle and cellular
structure and with Masson trichrome stain to delineate fibrous
tissue. All infarcts were examined histologically to verify that the
control dogs had transmural and myocyte-free defects. Rat hearts
were not histologically examined. By random selection of 5 low-
power fields (40 magnification) on light microscopy, the area of
grafted myoblasts in the CCT and myoblast groups’ infarcted scars
was quantified by using the following formula: Length/2 
Width/2.
Immunostaining for Neograft and Neovessels
Paraffin blocks were sectioned, deparaffinized, and immunostained
with the following antibodies: monoclonal antiskeletal myosin
antibody to fast-twitch skeletal myosin heavy chain (MHC), (MY-
32, Sigma); monoclonal antimyosin (skeletal, slow) directed
against skeletal slow MHC isoforms (NOQ7.5.4D, Sigma); and
troponin T (Cardiac Isoform specific, Ab-1, mouse monoclonal
antibody; NeoMarkers).
648 The Journal of Thoracic and Cardiovascular Surgery ● SeptThe nitrogen liquid frozen sections were immunostained with
an antibody to von Willebrand factor–horseradish peroxidase
(DAKO). Capillaries were counted by detecting the vascular en-
dothelial cells. Ten different fields at 100 magnification were
randomly selected, and the number of capillaries in each field was
counted and expressed for results as the number of vessels per
square millimeter.
Angiogenic Factor Presence
Syngeneic Lewis strain rats (n  16) were used for enzyme-linked
immunosorbent assay (ELISA) assessment of growth factors in
heart tissue and cultured cell supernatant. The 2-week ligated LAD
rats were used as CCT, myoblast, BM-MNC, and control groups,
and the VEGF ELISA kit (R&D Systems, Inc), bFGF ELISA kit
(Chemikon Int Inc) and human growth factor (HGF) ELISA kit
(Institute of Immunology, Tokyo) were used in our experiments.
The same ratio numbers of SMs, BM-MNCs and SMs plus BM-
MNCs (coculture) were cultured individually for in vitro measure-
ment of growth factors.
Statistical Analysis
All data are presented as means  SD. Differences in cardiac
performance data were analyzed between the groups by the 2-way
analysis of variance test. The other numerical data were analyzed
by 1-way analysis of variance. If a significant F ratio was obtained,
further analysis was carried out with the Turkey-Kramer post hoc
test.
Results
Global Cardiac Performance
All 4 groups showed no significant difference in baseline (2
weeks after LAD ligation) echocardiographic measure-
ments. The results after cell transplantation, however,
showed diversity in all groups, as shown in Figure 1. EF
measurements were 37.7% at baseline (average in 4 groups)
and after 4 weeks measured as follows: CCT group, 55.3%
 8.6%; myoblast group, 47.4%  7.4%; BM-MNC group,
44.4%  6.7%; and control group, 34.4%  5.4% (P 
.05). EF was only significant in the CCT group compared
with that seen in the other 3 groups (Figure 1, a). LV
end-systolic area was smaller in circumference after CCT
compared with that seen in the control and BM-MNC
groups and was also significantly smaller in the myoblast
group compared with that seen in the control group.
Percentage fractional area shortening was significantly
improved in the CCT group compared with that in all other
groups (Figure 1, b). The myoblast group also showed
improvement in cardiac performance, but this was not sig-
nificant compared with that seen in the CCT group. The
CCT group showed significant EF and fractional area short-
ening compared with that seen in the other groups. End-
diastolic area and end-systolic area was improved in the
CCT and myoblast groups compared with that seen in the
control group and showed no significant difference between
the CCT and myoblast groups. There was no significant
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Pdifference in improvement of cardiac function between the
BM-MNC and control groups.
Engrafted Myoblast Structure and Immunostaining
Stained specimens (Figure 2) revealed grafts containing
autologous skeletal muscle cells surviving within the
scarred tissue, and this cellularity replaced the collagenous
area. Hematoxylin and eosin staining clearly identified the
grafted cells as myoblasts, which appeared in the form of
multinucleated myofibers in the CCT and myoblast groups.
These myofibers were all grafted parallel after host cell
organization. Although a few surviving host cardiomyo-
cytes in the scar area stained positive for MHC slow, both
MHC fast and slow stained negative for SMs in the BM-
MNC and control groups.
After 4 weeks of cell transplantation, serial sections
immunostained by directing against the fast-MHC isoform
indicated the graft occupation by skeletal muscle structures,
mainly fast-twitch fibers. A small percentage, approxi-
mately 20%, stained positive for slow MHC, whereas ap-
proximately 40% of stained skeletal myofibers coexpressed
the slow and fast MHC isoforms. The same sections stained
negative with troponin T, specific for cardiac, reconfirming
their skeletal type identity (data not shown). No morpho-
logic differences between the myoblasts of the CCT and
myoblast groups were observed.
The measurements of graft diameter showed signifi-
cantly large myoblast grafts in CCT group hearts compared
Figure 1. Echocardiography at baseline (2 weeks af
transplantation. CCT demonstrated improved left ventri
shortening (FAS; b), left ventricular end-systolic area (L
M, Myoblast group; B, BM-MNC group; C, control grou
.05, CCT versus B; P < .05, M versus B. BL, Baselinwith those of the myoblast group. The graft sizes emerged
The Journal of Thoracias follows: 0.31  0.09 mm2 in the CCT group versus 0.11
 0.05 mm2 in the myoblast group (P  .05). On the basis
of the histologic measurements, the ratio of infarct area to
graft size area appeared to be around 1:1 in the CCT group
versus 5:1 in the myoblast group.
Effect of Cell Transplantation on Neovascularization
Immunostaining with antibodies to von Willebrand factor
confirmed the endothelial character of these neovessels.
Four groups were compared for neovascularization and
counted as follows: CCT group, 45.6 12; myoblast group,
26.5 8.1; BM-MNC group, 30.7 15; and control group,
7.1  1.4  102/mm2 (P  .05). Only the CCT group
showed the highest number of new vessels and significant
angiogenesis. Compared with the CCT group, the myoblast
and BM-MNC groups showed almost half the number of
vessels (Figure 3).
Presence of Angiogenic Factors
A markedly upregulated in vivo expression of VEGF was
measured in hearts transplanted with CCT compared with
those in the myoblast and BM-MNC groups (2.9  0.7 vs
0.24  0.7 vs 1.9  0.2 ng/g tissue, respectively; P  .05),
but VEGF expression was not significantly higher in CCT in
vitro cultures compared with that seen in myoblast and
BM-MNC cultures.
In vivo HGF was also highly expressed after CCT com-
pared with that seen in the myoblast and BM-MNC groups
he LAD ligation) and 4 weeks’ follow-up after cell
ejection fraction (LVEF; a), percentage fractional area
; c), and left ventricular end-diastolic area (LVEDA; d).
< .05 versus control; #P < .05, CCT versus M; †P <
, 4 weeks.ter t
cular
VESA
p. *P
e; 4W(3.4  1.5 vs 1.4  0.3 vs 1.8  0.3 ng/g tissue, respec-
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observed in in vitro cultures. The in vivo bFGF expression
level was lower but detectable in all 3 cell transplantation
groups and was not significant between cell therapy groups.
Infarcted hearts without any cell transplantation showed
minimal detectable VEGF and bFGF expression (Figure 4).
Discussion
The current study demonstrates that the transplantation of
autologous SMs induces further improved cardiac perfor-
mance after the addition of BM-MNCs. The myoblasts
attained their skeletal-type character after engrafting with-
out showing phenotypic conversion to cardiomyocytes. The
release of various growth factors was also highly expressed
in the CCT group. We observed that the myoblasts com-
bined with multipotent BM-MNCs are capable of surplus
significant improvement in the deteriorated postinfarction
LV function, with enhancement of cardiac performance and
attenuation of cardiac remodeling.
After cell transplantation, the transplanted cells enter a
Figure 2. 1A-1D, CCT group; 2A-2D, myoblast group; 3A
fication (100). 1A and 2A shows survived grafted ske
myoblast groups. 1C and 2C show the fast-MHC expre
1D and 2D present slow-MHC expression, showing cha
(5A-5D) demonstrates the elongated and multinuclear s
and eosin stain; 1B, 2B, 3B, 4B, and 5B, Masson trichr
MHC slow stain.new phase during which their destiny is still at stake. The in
650 The Journal of Thoracic and Cardiovascular Surgery ● Septvivo environment plays a crucial role for the outcome of
injected cells because they need an optimal microenviron-
ment to home themselves.8 Cell transplantation with angio-
genic factor gene transfection (ie, VEGF or HGF) showed
better cardiac performance,10,17 but for clinical use, impor-
tant issues like tumorigenesis, cell toxicity, immature vessel
formation, and unregulated expression of transfected
growth factors18 must be eliminated. Moreover, the release
of cytokines from the transplanted cells is under strict
physiologic control and occurs according to the in vivo
microenvironment needs, and thus it is safer.19 Myoblasts
and BMCs act as the natural supplier of HGF and VEGF,
respectively, and provide feasible and safer therapy for
clinical application.
A supporting CCT study of myoblasts and BM-MNCs in
another small animal experiment by Ott and associates20 has
shown the benefits of combining 2 potential cell lines for
better cardiac performance and has also shown that the
engraftment of SMs is more effective in combined trans-
plantation of SMs and BM-MNCs compared with in iso-
BM-MNC group; 4A-4B, control group at low magni-
myofibers in the myocardial scar area in the CCT and
by myoblasts, showing their skeletal muscle nature.
in twitch from fast to slow. High magnification, 400,
ture of myoblasts. 1A, 2A, 3A, 4A, and 5A, hematoxylin
stain; 1C, 2C, and 5C, MHC fast stain; 1D, 2D, and 5D,-3B,
letal
ssion
nge
truc
omelated transplantation of SMs. One interesting finding of Ott
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Pand associates is that in combination with BM-MNCs (5 
106), half of the number of transplanted SMs (5  106) was
as effective in restoring LV function and inducing angio-
genesis as in isolated transplantation of SMs (107). Similar
to our study, their experiment did not show higher angio-
genesis in the BMC transplantation group. Only our study
has evaluated the expression of different growth factors and
suggests it as one of the possible underlying mechanism for
this effective combined therapy.
Our results suggest that a one-time dose of BMCs is
capable of introducing significant angiogenesis, leading to
better cardiac performance. The angiogenesis count was
highest because of CCT and was widespread in and around
the scar area. The reasoning for our results is that the
endothelial cells and cytokines supplied by BM-MNCs im-
prove the blood perfusion,11 thereby probably playing a
pivotal role for better myoblast survival and heart function.
The initial release of VEGF into the local environment in
prolonging the survival of the cells that are not irreversibly
damaged until angiogenesis is initiated might be the possi-
ble reason for early myoblast, as well as host cardiomyo-
cyte, survival and is also probably helpful in retarding the
Figure 3. Staining with anti-factor VIII antibody for the endothe-
lial cells. Capillary density comparison among the 4 groups
showed a significantly higher number of vessels in the CCT group
compared with numbers in the other cell transplantation groups
(*P < .05 vs control). M, Myoblast group; B, BM-MNC group; C,
control group.further deterioration of ischemic heart. In addition, use of
The Journal of ThoraciVEGF benefits myoblasts for their migration and survival21
and might be a vital support. Another available benefit is the
release and use of HGF, a unique angiogenic and fibrosis-
preventing factor, by the transplanted myoblasts for their
own growth and recruitment of other cells.22 Although
VEGF and HGF expression was higher in the CCT in vivo
study, we are unaware of the exact physiologic reasons that
might be involved in showing their opposite expression
pattern in in vitro cultures. We believe that the response of
cells (myoblasts and BM-MNCs) and the release of growth
factors occur according to their microenvironment needs,
and their cellular interaction might be an autoadjusting
factor.
Grafted myoblasts accomplish the task of myogenesis,
and this attained neomuscle mass plays a primary role in
reremodeling the geometry of the LV chamber, as well as
providing mechanical support. The grafted myoblasts in the
CCT group mainly appeared in the form of large grafted
Figure 4. Detection of VEGF, bFGF, and HGF at day 5 after cell
transplantation, as measured by means of ELISA in recipient rat
hearts (n  4 in each group). M, Myoblast group; B, BM-MNC
group; C, control group; ND, less than the limit of detection. *P <
.05 versus control; #P < .05, CCT versus M; P < .05, CCT versus
B; †P < .05, B versus M.bundles of myofibers and occupied the scar area wide-
c and Cardiovascular Surgery ● Volume 130, Number 3 651
Cardiopulmonary Support and Physiology Memon et al
CSPspread, whereas the myoblast group showed small-sized
myoblast grafts. Recent reports mentioned the possible role
of stromal cell–derived factor 1 in recruiting the stem
cells.23 Because stromal cell– derived factor 1 is secreted in
muscle tissue and muscle satellite cells express the func-
tional CXCR4 receptors,24 they might chemoattract stem
cells to the site of the need and might be beneficial for heart
repair.
We found no contradiction with Reinecke and coworkers25
in observing the fate of transplanted SMs at 4 weeks. Our
transplanted myoblasts expressed fast and slow skeletal MHC
and did not transdifferentiate into cardiomyocytes after graft-
ing. Because of deregulation and disappearance of intercalated
disk protein (connexin 43) expression by grafted myoblasts in
the mature stage,26 there is enough evidence for the absence of
electromechanical coupling between host and grafted cells.27
Moreover, it has been reported that the transplanted BMCs do
not induce electromechanical integration with host myocardi-
um.28 Because SMs and BMCs do not form a gap junction in
vivo, the chances that the cells will cause arrhythmia is also
reduced.
One of the limitations of this study is justification of the
comparison of adequate cell numbers in each group. The
cell numbers among the CCT versus BM-MNC and myo-
blast versus BM-MNC groups are relatively different. How-
ever, such differences in numbers of cells between the CCT
and myoblast groups is relatively small compared with the
greater difference between their cardiac improvements, and
this suggests that the efficiency and potentiality of CCT is
far greater than just increasing the cell numbers of the same
cell type.
In a previous clinical trial study, only 1.5 106 BM cells
were injected into patients undergoing coronary artery by-
pass grafting. The group showed improved perfusion, lead-
ing to better cardiac performance.29 Selection of 1  108
myoblasts and 3  106 BM-MNCs in our study is relevant
to the number of cells used in the previous clinical trial
studies.1,29
The limited number of BMCs and myoblasts used is to
avoid the possibility of side effects, such as osteoformation
by BMCs or arrhythmia by myoblasts. We confirmed neg-
ative osteoformation by calcium staining. High numbers of
BMCs might release excessive growth factors and might
lead to other calcification consequences. With 3  106
BM-MNCs transplanted, we observed no bone formation,
suggesting an adequate cell supply. On the other hand, we
did not detect arrhythmia in any of the myoblast-trans-
planted animals, as monitored by electrocardiography dur-
ing echocardiography. Although the study by Menasché and
colleagues1 showed 8.7  108 myoblast transplantation to
be arrythomogenic, another 2-year follow-up clinical study
trial in 18 patients with a variable but lesser number of
transplanted myoblasts (10  106 to 3  108) has shown
652 The Journal of Thoracic and Cardiovascular Surgery ● Septmyoblast transplantation to be a safe and nonarrhythmo-
genic therapy for ischemic cardiomyopathy.30 We believe
that further increasing the number of myoblasts and BMCs
is cautionary.
There are a few other limitations to our study. First, dogs
are known to have native collateral vessels in the heart, and
therefore it is possible that such native collateral formation
might affect the functional recovery, but on the basis of the
baseline (pretransplantation) cardiac performance values
showing infarct formation in all groups, we believe that our
overall conclusions were not distorted. In addition, although
the coronary blood flow measurement is missing in our exper-
iment, the absence of significant angiogenesis and lower
growth factor expression in the BM-MNC and myoblast
groups can be taken as supporting evidence for the ineffective-
ness of native collateral vessels on results after cell transplan-
tation. Second, we did not assess the size of infarction after cell
transplantation. Third, the activation of the endogenous path-
way for cardiac repair by growth factors from implanted cells
is not measured and demonstrated. Further studies eliminating
such drawbacks and examining BMC in vivo differentiation
and their ability to generate phenotypes must be conducted.
Additional improvement with CCT is probably due to
establishment and enrichment of the scar area with suitable
microenvironment for the myoblasts and the host cardiomy-
ocytes. This collaboration of different autologous cells and
their growth factors should be appreciated and could be
used for clinical benefit. Combined cellular cardiomyo-
plasty with SMs and BM-MNCs had been shown to be a
novel myocardial repair strategy for treating ischemic heart
failure.
We thank Shigeru Matsumi for his technical assistance.
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